Download PDF
Semin Respir Crit Care Med 2011; 32(5): 651-660
DOI: 10.1055/s-0031-1287873
© Thieme Medical Publishers

Hematologic Failure

Marcel Levi1 , Marcus Schultz2
  • 1Department of Vascular Medicine/Internal Medicine, University of Amsterdam, The Netherlands
  • 2Department of Intensive Care, Academic Medical Centre, University of Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
11 October 2011 (online)

    Permissions and Reprints

ABSTRACT

Hematologic factors, in particular platelets and the coagulation system, play an important role in the pathogenesis of organ failure in the intensive care unit. Failure of these hematologic systems is common in intensive care patients and may range from isolated thrombocytopenia or prolonged global clotting tests to complex defects, such as disseminated intravascular coagulation. There are many causes for a deranged coagulation in critically ill patients, and each of these underlying disorders may require specific therapeutic management. Hence, a proper differential diagnosis and initiation of adequate (supportive) treatment strategies are crucial to reduce morbidity and mortality in critically ill patients with coagulation abnormalities.

KEYWORDS

Coagulation - platelets - intensive care - disseminated intravascular coagulation - thrombotic microangiopathy - heparin-induced thrombocytopenia - bleeding

REFERENCES

  • 1 Levi M, Opal S M. Coagulation abnormalities in critically ill patients.  Crit Care. 2006;  10 (4) 222
    CrossrefPubMedGoogle Scholar
  • 2 Vanderschueren S, De Weerdt A, Malbrain M et al.. Thrombocytopenia and prognosis in intensive care.  Crit Care Med. 2000;  28 (6) 1871-1876
    CrossrefPubMedGoogle Scholar
  • 3 Ahmed A, Kojicic M, Herasevich V, Gajic O. Early identification of patients with or at risk of acute lung injury.  Neth J Med. 2009;  67 (9) 268-271
    PubMedGoogle Scholar
  • 4 Schultz M J. Early recognition of critically ill patients.  Neth J Med. 2009;  67 (9) 266-267
    PubMedGoogle Scholar
  • 5 Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn E G. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome.  Crit Care Med. 2002;  30 (8) 1765-1771
    CrossrefPubMedGoogle Scholar
  • 6 Shorr A F, Thomas S J, Alkins S A, Fitzpatrick T M, Ling G S. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients.  Chest. 2002;  121 (4) 1262-1268
    CrossrefPubMedGoogle Scholar
  • 7 Bernard G R, Vincent J L, Laterre P F Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group et al. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 (10) 699-709
    CrossrefPubMedGoogle Scholar
  • 8 Anas A A, Wiersinga W J, de Vos A F, van der Poll T. Recent insights into the pathogenesis of bacterial sepsis.  Neth J Med. 2010;  68 (4) 147-152
    PubMedGoogle Scholar
  • 9 Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients.  Semin Thromb Hemost. 2008;  34 (5) 459-468
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Levi M, Nieuwdorp M, van der Poll T, Stroes E. Metabolic modulation of inflammation-induced activation of coagulation.  Semin Thromb Hemost. 2008;  34 (1) 26-32
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Griffin J H, Fernández J A, Gale A J, Mosnier L O. Activated protein C.  J Thromb Haemost. 2007;  5 (Suppl 1) 73-80
    CrossrefPubMedGoogle Scholar
  • 12 Esmon C T. Role of coagulation inhibitors in inflammation.  Thromb Haemost. 2001;  86 (1) 51-56
    PubMedGoogle Scholar
  • 13 Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.  Crit Care Med. 2001;  29 (7, Suppl) S90-S94
    CrossrefPubMedGoogle Scholar
  • 14 Esmon C T. The regulation of natural anticoagulant pathways.  Science. 1987;  235 (4794) 1348-1352
    CrossrefPubMedGoogle Scholar
  • 15 Esmon C T. The endothelial cell protein C receptor.  Thromb Haemost. 2000;  83 (5) 639-643
    PubMedGoogle Scholar
  • 16 Mesters R M, Helterbrand J, Utterback B G et al.. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications.  Crit Care Med. 2000;  28 (7) 2209-2216
    PubMedGoogle Scholar
  • 17 Vary T C, Kimball S R. Regulation of hepatic protein synthesis in chronic inflammation and sepsis.  Am J Physiol. 1992;  262 (2 Pt 1) C445-C452
    PubMedGoogle Scholar
  • 18 Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein C degradation in vitro by neutrophil elastase.  Biol Chem Hoppe Seyler. 1991;  372 (11) 1007-1013
    CrossrefPubMedGoogle Scholar
  • 19 Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor.  J Exp Med. 1986;  163 (3) 740-745
    CrossrefPubMedGoogle Scholar
  • 20 Faust S N, Levin M, Harrison O B et al.. Dysfunction of endothelial protein C activation in severe meningococcal sepsis.  N Engl J Med. 2001;  345 (6) 408-416
    CrossrefPubMedGoogle Scholar
  • 21 Taylor Jr F BJ, Stearns-Kurosawa D J, Kurosawa S et al.. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis.  Blood. 2000;  95 (5) 1680-1686
    PubMedGoogle Scholar
  • 22 Levi M, van der Poll T, Büller H R. Bidirectional relation between inflammation and coagulation.  Circulation. 2004;  109 (22) 2698-2704
    CrossrefPubMedGoogle Scholar
  • 23 Levi M. Platelets.  Crit Care Med. 2005;  33 (12, Suppl) S523-S525
    CrossrefPubMedGoogle Scholar
  • 24 Levi M, Löwenberg E C. Thrombocytopenia in critically ill patients.  Semin Thromb Hemost. 2008;  34 (5) 417-424
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Löwenberg E C, Meijers J C, Levi M. Platelet-vessel wall interaction in health and disease.  Neth J Med. 2010;  68 (6) 242-251
    PubMedGoogle Scholar
  • 26 Hawiger J J. Adhesive interactions of blood cells and the vascular wall in hemostasis and thrombosis. In: Colman R W, ed. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, PA: JB Lippincott; 1994: 639-653
    Google Scholar
  • 27 Ware J A, Heistad D D. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions.  N Engl J Med. 1993;  328 (9) 628-635
    CrossrefPubMedGoogle Scholar
  • 28 Woodside D G, Liu S, Ginsberg M H. Integrin activation.  Thromb Haemost. 2001;  86 (1) 316-323
    PubMedGoogle Scholar
  • 29 Ruggeri Z M. Platelets in atherothrombosis.  Nat Med. 2002;  8 (11) 1227-1234
    CrossrefPubMedGoogle Scholar
  • 30 Ruggeri Z M. Von Willebrand factor, platelets and endothelial cell interactions.  J Thromb Haemost. 2003;  1 (7) 1335-1342
    CrossrefPubMedGoogle Scholar
  • 31 Arya M, Anvari B, Romo G M et al.. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers.  Blood. 2002;  99 (11) 3971-3977
    CrossrefPubMedGoogle Scholar
  • 32 Sporn L A, Marder V J, Wagner D D. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively.  Blood. 1987;  69 (5) 1531-1534
    PubMedGoogle Scholar
  • 33 Tsai H M, Nagel R L, Hatcher V B, Sussman I I. Multimeric composition of endothelial cell-derived von Willebrand factor.  Blood. 1989;  73 (8) 2074-2076
    PubMedGoogle Scholar
  • 34 George J N, Sadler J E, Lämmle B. Platelets: thrombotic thrombocytopenic purpura.  Hematology (Am Soc Hematol Educ Program). 2002;  315-334
    PubMedGoogle Scholar
  • 35 Hurskainen T L, Hirohata S, Seldin M F, Apte S S. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family.  J Biol Chem. 1999;  274 (36) 25555-25563
    CrossrefPubMedGoogle Scholar
  • 36 Moake J L. Thrombotic microangiopathies.  N Engl J Med. 2002;  347 (8) 589-600
    CrossrefPubMedGoogle Scholar
  • 37 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 (22) 1585-1594
    CrossrefPubMedGoogle Scholar
  • 38 Furlan M, Robles R, Galbusera M et al.. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 (22) 1578-1584
    CrossrefPubMedGoogle Scholar
  • 39 Mavrommatis A C, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis.  Crit Care Med. 2000;  28 (2) 451-457
    CrossrefPubMedGoogle Scholar
  • 40 Folman C C, Linthorst G E, van Mourik J et al.. Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis?.  Thromb Haemost. 2000;  83 (6) 923-930
    PubMedGoogle Scholar
  • 41 François B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor.  Am J Med. 1997;  103 (2) 114-120
    CrossrefPubMedGoogle Scholar
  • 42 Warkentin T E, Aird W C, Rand J H. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome.  Hematology (Am Soc Hematol Educ Program). 2003;  497-519
    PubMedGoogle Scholar
  • 43 Verma A K, Levine M, Shalansky S J, Carter C J, Kelton J G. Frequency of heparin-induced thrombocytopenia in critical care patients.  Pharmacotherapy. 2003;  23 (6) 745-753
    CrossrefPubMedGoogle Scholar
  • 44 Warkentin T E. Heparin-induced thrombocytopenia: pathogenesis and management.  Br J Haematol. 2003;  121 (4) 535-555
    CrossrefPubMedGoogle Scholar
  • 45 Tsai H M. Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura.  Arterioscler Thromb Vasc Biol. 2003;  23 (3) 388-396
    CrossrefPubMedGoogle Scholar
  • 46 van den Born B J, van der Hoeven N V, Groot E et al.. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.  Hypertension. 2008;  51 (4) 862-866
    CrossrefPubMedGoogle Scholar
  • 47 Stéphan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU.  Chest. 1999;  115 (5) 1363-1370
    CrossrefPubMedGoogle Scholar
  • 48 Greaves M, Preston F E. Approach to the bleeding patient. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 1031-1043
    Google Scholar
  • 49 Edmunds L H. Hemostatic problems in surgical patients. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, PA: Lippincott William &Wilkins; 2001: 1031-1043
    Google Scholar
  • 50 Bailey B, Amre D K, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation.  Crit Care Med. 2003;  31 (1) 299-305
    CrossrefPubMedGoogle Scholar
  • 51 Vlaar A P, Schultz M J, Juffermans N P. Transfusion-related acute lung injury: a change of perspective.  Neth J Med. 2009;  67 (10) 320-326
    PubMedGoogle Scholar
  • 52 Levi M M, Eerenberg E, Löwenberg E, Kamphuisen P W. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management.  Neth J Med. 2010;  68 (2) 68-76
    PubMedGoogle Scholar
  • 53 Levi M, Ten Cate H. Disseminated intravascular coagulation.  N Engl J Med. 1999;  341 (8) 586-592
    CrossrefPubMedGoogle Scholar
  • 54 Wheeler A P, Bernard G R. Treating patients with severe sepsis.  N Engl J Med. 1999;  340 (3) 207-214
    CrossrefPubMedGoogle Scholar
  • 55 Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights.  Semin Thromb Hemost. 2008;  34 (8) 742-746
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Levi M, Toh C H, Thachil J, Watson H G. British Committee for Standards in Haematology . Guidelines for the diagnosis and management of disseminated intravascular coagulation.  Br J Haematol. 2009;  145 (1) 24-33
    CrossrefPubMedGoogle Scholar
  • 57 Taylor Jr F BJ, Toh C H, Hoots W K, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.  Thromb Haemost. 2001;  86 (5) 1327-1330
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Dhainaut J F, Yan S B, Joyce D E et al.. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.  J Thromb Haemost. 2004;  2 (11) 1924-1933
    CrossrefPubMedGoogle Scholar
  • 59 Hermanides J, Huijgen R, Henny C P et al.. Hip surgery sequentially induces stress hyperglycaemia and activates coagulation.  Neth J Med. 2009;  67 (6) 226-229
    PubMedGoogle Scholar
  • 60 Hirsh J, Heddle N, Kelton J G. Treatment of heparin-induced thrombocytopenia: a critical review.  Arch Intern Med. 2004;  164 (4) 361-369
    CrossrefPubMedGoogle Scholar
  • 61 Hellstern P, Muntean W, Schramm W, Seifried E, Solheim B G. Practical guidelines for the clinical use of plasma.  Thromb Res. 2002;  107 (Suppl 1) S53-S57
    CrossrefPubMedGoogle Scholar
  • 62 Mannucci P M, Levi M. Prevention and treatment of major blood loss.  N Engl J Med. 2007;  356 (22) 2301-2311
    CrossrefPubMedGoogle Scholar
  • 63 Mannucci P M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.  Blood. 1997;  90 (7) 2515-2521
    PubMedGoogle Scholar
  • 64 Levi M, Cromheecke M E, de Jonge E et al.. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.  Lancet. 1999;  354 (9194) 1940-1947
    CrossrefPubMedGoogle Scholar
  • 65 Porte R J, Molenaar I Q, Begliomini B et al. EMSALT Study Group. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study.  Lancet. 2000;  355 (9212) 1303-1309
    CrossrefPubMedGoogle Scholar
  • 66 Levi M, Levy M, Williams M D et al. Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).  Am J Respir Crit Care Med. 2007;  176 (5) 483-490
    CrossrefPubMedGoogle Scholar

Marcel LeviM.D. Ph.D. 

Department of Vascular Medicine/Internal Medicine, Academic Medical Centre F-4

Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Email: m.m.levi@amc.uva.nl

      >